Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount
Amjevita Biosimilar Version Of Adalimumab Has Six Months With The Market To Itself
Executive Summary
Amgen has confirmed its long-awaited launch of Amjevita, the first US biosimilar rival to Humira, kicking off a year of competition that will also see a second wave of adalimumab products launch in six months’ time. The company has announced that it will offer the product at a 55% discount to the originator.
You may also be interested in...
AbbVie Hails Humira’s Resistance To US Competition
As the firm reported Q2 results, AbbVie management offered some insights into how Humira is standing up against US biosimilar adalimumab competition a little better than expected.
The Next Wave Of US Humira Biosimilars
Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.
Generics Bulletin Explains: The Next Wave Of US Humira Biosimilars
Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.